Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers
- 64 Downloads
The kinetics of oxiracetam after single intravenous and oral doses (2000 mg) were investigated in four healthy volunteers. Following intravenous administration, the decline in serum levels showed a prolonged, rapid phase followed by a delayed terminal phase. Mean residence times ranged from 3.9 to 6.5 h. Volumes of distribution ranged from 0.9 to 1.81 · kg−1, whereas clearance values ranged from 100 to 119 ml·.h−1· kg -1 More than 90% of the intravenous dose was recovered unchanged in the urine within 48 h. Oral administration resulted in peak levels within 1–2 h; thereafter, the decline in serum levels showed a pattern similar to that observed after the intravenous dose — almost 50% of the oral dose was excreted in the urine within 6 h. The absolute availability of oral oxiracetam was 75 ± 7%.
Key-wordsPharmacokinetics oxiracetam bioavailability
Unable to display preview. Download preview PDF.
- 1.Banfi S., Cornelli U. and Carpi C. (1977): Pharmacological study on learning and memory tests of a new compound : 4-hydroxy-2-oxo-l-pyrrolidinacetamide (ISF 2522). VI Int. Meeting Int. Society for Neurochemistry, Copenhagen, 21–26 August 1977. 274Google Scholar
- 2.Banfi S., Semeraro C, Allievi E., Fonio W. and Dorigotti L. (1981): Impaired learning rate of SH rats with cerebrovascular lesions: effect of oxiracetam (ISF 2522), a new nootropic agent. Int. Symp. on Cerebrovascular Diseases, Gardone, 2–4 July 1981.Google Scholar
- 3.Fratini F., Teza E., Gaiti A., Porcellati G. (1977): The effect on brain metabolism of 4-hydroxy-2-oxo-l-pyrro-Iidinacetamide. VI Int. Meeting Int. Society for Neuro-chemistry, Copenhagen, 21–26 August 1977.Google Scholar
- 4.Pedata F., Moroni F., Banfi S. and Pepeu G. (1983): Effects of nootropic drugs on brain cholinergic mechansism: biochemical and behavioral investigations. Int. Conference on the Dynamics of Cholinergic Mechanisms, Ogleby, West Virginia, 30 October–4 November 1983.Google Scholar
- 5.Itil T.M., Soldatos C, Bozak M., Ramadanoglu E., Dayican G., Morgan V. and Menon G.N. (1979): Curr. Ther. Res., CNS effects of ISF 2522, a new nootropic (a phase I safety and CNS-efficacy study with quantitative pharmaco-EEG and pharmaco-psychology),26, 525–538.Google Scholar
- 7.Perucca E. and Richens A. (1979): Br. J. Clin. Pharmacol., Reduction of oral bioavailability of lignocaine by induction of first-pass metabolism in epileptic patients,5, 21–31.Google Scholar
- 8.Wagner J.G. (1969): Pharmacokinetics, Richards Laboratories, Grosse Point.Google Scholar
- 10.Riggs D.S. (1963): The mathematical approach to physiological problems, Williams and Wilkins, Baltimore.Google Scholar